Molecular stool screening for colorectal cancer
- 29 July 2000
- Vol. 321 (7256), 254-255
- https://doi.org/10.1136/bmj.321.7256.254
Abstract
Colorectal cancer is the most common fatal malignancy among non-smokers in North America and Europe. Better tools are needed to improve the accuracy, compliance rates, safety, and affordability of screening. Stool testing has several important advantages over structural screening methods and warrants more investigation. Stool testing is non-invasive, avoids unpleasant cathartic preparation, can be performed on transported specimens without people having to visit their physicians, and, unlike sigmoidoscopy, reflects the state of the full length of the colorectum. Screening for stool markers that are more accurate than occult blood could substantially improve screening outcomes, and there is a strong biological rationale for targeting the DNA alterations that are exfoliated from neoplasms. Faecal occult blood testing, used to screen for colorectal cancer for nearly three decades, continues to be the most widely used tool. Although controlled trials have shown that is of significant benefit, deaths from colorectal cancer have only been reduced by 15-33% after 10–14 years, and it has had no real impact on reducing the cumulative incidence of cancer.1–3 These outcomes are …This publication has 11 references indexed in Scilit:
- Colorectal cancer screening by detection of altered human DNA in stool: Feasibility of a multitarget assay panelGastroenterology, 2000
- Morphometric analysis of the “mucocellular layer” overlying colorectal cancer and normal mucosa: Relevance to exfoliation and stool screeningHuman Pathology, 2000
- Genetic Instability and Chromosomal Aberrations in Colorectal Cancer: A Review of the Current ModelsCancer Detection Prevention, 1998
- Quantitation of DNA from exfoliated colonocytes isolated from human stool surface as a novel noninvasive screening test for colorectal cancer.1998
- FECAL OCCULT BLOOD TESTING FOR COLORECTAL CANCER: Can We Afford to Do This?Gastroenterology Clinics of North America, 1997
- Randomised study of screening for colorectal cancer with faecal-occult-blood testThe Lancet, 1996
- Randomised controlled trial of faecal-occult-blood screening for colorectal cancerThe Lancet, 1996
- Mutations of the p53 gene in the stool of patients with resectable colorectal cancerCancer, 1996
- Reducing Mortality from Colorectal Cancer by Screening for Fecal Occult BloodNew England Journal of Medicine, 1993
- Identification of ras Oncogene Mutations in the Stool of Patients with Curable Colorectal TumorsScience, 1992